医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EOS imaging Obtains Marketing Approval in South Korea

2014年10月28日 AM04:29
このエントリーをはてなブックマークに追加


 

PARIS

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopaedic medical imaging, today announced that the Company has received approval from the Korean Food and Drug Administration (KFDA) to market the EOS® system in South Korea, further expanding the Company’s commercial opportunities in the fast growing Asia Pacific market. The Company has now obtained authorization to market its technology in 34 countries.

Approval to market the EOS system in South Korea follows similar regional authorizations in Japan and Taiwan and represents a significant milestone as the region continues to adopt EOS’ technology for orthopaedic imaging. The KFDA approval will enable the Company to continue expanding its presence in the Asia Pacific medical imaging market, which is predicted to see the highest growth globally during the next 5 years1.

To develop the Korean market, EOS has established a distribution partnership with DK Medical Solutions (DKMS), a company established in 1986 and specialized in the import and sales of high end medical equipment, in particular imaging equipment.

Marie Meynadier, CEO of EOS imaging, comments on this new authorization: “This marketing approval in South Korea is yet another great milestone and success for our Company. We are proud to be able to offer our technology in Asia’s third largest medical device market and increase our commercial deployment throughout the fast growing Asia Pacific market.

About EOS imaging:

EOS imaging designs, develops, and markets EOS® and associated solutions, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market in 34 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

EOS imaging is listed on Compartment C of the Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

1 Medical Imaging Equipment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019, Transparency Market Research

CONTACT

Anne Renevot
CFO
Ph: +33 (0)1 55 25 61 24
investors@eos-imaging.com
or
NewCap
Financial
communication and investor relations
Sophie Boulila / Pierre Laurent
Ph:
+33 (0)1 44 71 94 91 – eosimaging@newcap.fr
or
The
Ruth Group (US)

Press relations / Calvin Allen
Ph:
646-536-7002
callen@theruthgroup.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結
  • 国際的な食品・飲料企業の連合が、世界の供給食料から人工トランス脂肪酸を排除するための世界保健機関とResolve to Save Livesによる呼び掛けを支持